ForumIAS LATEST
- 07 Sept. | From Preparation to Mains Readiness: Making the Next Four Months Count Click Here to Read More →
- 07 Sept. | Interview Preparation & Way Ahead After Mains 2026 by Ayush Sir Click Here to Register →
- 07 Sept. | Do you know what is better than MGP and Current Affairs? Click Here to Read More →
- 31 Aug. | Upcoming programs by forumiAS For UPSC CSE 2027 Click Here to Read More →
News: Drugs Controller General of India(DCGI) has given approval to Serum Institute of India(SII) to conduct Phase II+III clinical trials of Oxford University AstraZeneca COVID-19 vaccine(COVISHIELD).
Facts:
- COVISHIELD: The Oxford vaccine “AZD1222” is being called Covishield in India.
- The Serum Institute of India(SII) has entered into a manufacturing partnership with biopharma major AstraZeneca to produce this Oxford vaccine.
Additional Facts:
- DCGI: It is a department of the Central Drugs Standard Control Organization(CDSCO) responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids and vaccines in India.It comes under the Ministry of Health & Family Welfare.
- Case Fatality Rate(CFR): It is the proportion of deaths from a certain disease compared to the total number of people diagnosed with the disease for a particular period.
